Functional genomics and CRISPR screening are transforming target identification by linking genes and pathways to disease-relevant phenotypes. By enabling efficient gene knockout, activation, or inhibition, CRISPR-based approaches help uncover causal biology, strengthen therapeutic hypotheses, and prioritize high-value targets for drug discovery.
Evotec integrates arrayed and pooled CRISPR screening with disease-relevant human in vitro models, advanced assay readouts, automated workflows, and AI-enabled data analysis. This end-to-end platform supports robust novel target identification across therapeutic areas, generating high-confidence data to guide target selection and accelerate progression into validation.
At Evotec
>100
CRISPR screens run in pooled and 96, 384, or 1536-well plate formats
>50
Cellular disease models used successfully, including 2D, 3D, primary and iPSC-derived
<3 months
For typical CRISPR assay development
>100
CRISPR screens run in pooled and 96, 384, or 1536-well plate formats
>50
Cellular disease models used successfully, including 2D, 3D, primary and iPSC-derived
<3 months
For typical CRISPR assay development
Evotec CRISPR Screening Expertise for Target Identification
Evotec’s CRISPR screening and genetic perturbation platform provides end-to-end support for target identification by functional genomics, aligning screening scale, disease model relevance, assay readouts, and data analysis with your therapeutic objectives. The result is robust, high-confidence data to support informed target selection and prioritization.
- Adaptable workflows across cellular models: Optimized protocols for cell lines, primary cells, and iPSC-derived cells in 2D and 3D formats, with flexible onboarding of new models across therapeutic areas.
- Accelerated assay development: Streamlined CRISPR assay setup and optimization of genetic perturbation protocols, typically within 2–3 months for a new cell model.
- Scalable arrayed CRISPR screening: High-throughput screening across 96-, 384-, and 1536-well plate formats, supporting focused studies through large-scale screening campaigns.
- Genome-scale screening capability and beyond: Integration with Evotec’s high-throughput automation infrastructure and data analysis pipelines enables efficient whole-genome CRISPR screens within weeks.
- Ready-to-use CRISPR libraries: In-house state-of-the-art whole-genome arrayed CRISPR libraries support rapid project initiation and faster time to data.
- Diverse assay readouts: Compatibility with high-content imaging, Cell Painting, transcriptomics, proteomics, flow cytometry, FLIPR, HTRF, Meso Scale Discovery, and other phenotypic or functional endpoints.
- Broad genetic perturbation toolbox: CRISPR-KO, CRISPRa, CRISPRi, siRNA, and shRNA approaches using synthetic gRNAs, RNP formats, or vector-based systems, including lentiviral and AAV delivery.
- AI-enabled data analysis: Advanced analysis groups genes into functional modules, links targets to pathways, reduces false positives, captures sub-threshold signals, and supports mechanism-of-action insights.
- Support beyond target identification: Applicable to target validation, target deconvolution, mechanism-of-action studies, combinatorial CRISPR-compound screening, and broader drug discovery workflows.
What Differentiates Evotec’s CRISPR Screening Platform
Evotec combines deep CRISPR and genetic perturbation screening expertise with decades of high-throughput screening experience, advanced human disease models, and information-rich assay readouts. Our integrated platform connects model selection, assay development, automated screening, and AI-enabled pathway analysis into scalable workflows that deliver robust, decision-ready data. This enables confident target selection, faster target validation, and more efficient progression toward therapeutic discovery.
Figure 1: Evotec’s Arrayed CRISPR Screening Workflow for Target Identification
